AVBP Stock Forecast 2025-2026
Distance to AVBP Price Targets
AVBP Price Momentum
10 Quality Stocks Worth Considering Now
Researching Arrivent (AVBP) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AVBP and similar high-potential opportunities.
Latest AVBP Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, AVBP has a bullish consensus with a median price target of $39.00 (ranging from $36.00 to $45.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $18.14, the median forecast implies a 115.0% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Schmidt at Guggenheim, projecting a 148.1% upside. Conversely, the most conservative target is provided by Robert Burns at HC Wainwright & Co., suggesting a 98.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AVBP Analyst Ratings
AVBP Price Target Range
Latest AVBP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AVBP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 20, 2025 | B. Riley Securities | Kalpit Patel | Buy | Initiates | $37.00 |
| Mar 10, 2025 | Guggenheim | Michael Schmidt | Buy | Initiates | $45.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $39.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $39.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $36.00 |
| Sep 11, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $36.00 |
| Sep 10, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $39.00 |
| Sep 10, 2024 | Goldman Sachs | Corinne Johnson | Buy | Maintains | $38.00 |
| Sep 10, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $36.00 |
| Aug 16, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $30.00 |
| Aug 15, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $35.00 |
| Jun 6, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $25.00 |
| May 9, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $25.00 |
| Apr 30, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Initiates | $25.00 |
| Feb 20, 2024 | Goldman Sachs | Corinne Johnson | Buy | Initiates | $27.00 |
| Feb 20, 2024 | Jefferies | Kelly Shi | Buy | Initiates | $35.00 |
| Feb 20, 2024 | Citigroup | Yigal Nochomovitz | Buy | Initiates | $30.00 |
Arrivent Biopharma Inc. (AVBP) Competitors
The following stocks are similar to Arrivent based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Arrivent Biopharma Inc. (AVBP) Financial Data
Arrivent Biopharma Inc. has a market capitalization of $617.05M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -39.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Arrivent Biopharma Inc. (AVBP) Business Model
About Arrivent Biopharma Inc.
Develops innovative cancer therapies.
Arrivent Biopharma generates revenue through the discovery, development, and commercialization of therapeutic candidates in oncology. The company collaborates with research institutions and pharmaceutical partners to enhance the drug development process, focusing on addressing unmet medical needs in cancer treatment.
With a strong pipeline targeting various cancer types, Arrivent Biopharma is well-positioned in the healthcare industry. Its emphasis on innovation and strategic partnerships aims to transform cancer treatment, aligning with industry trends toward personalized medicine and accelerated clinical pathways.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
52
CEO
Dr. Zhengbin Yao Ph.D.
Country
United States
IPO Year
2014
Website
arrivent.comArrivent Biopharma Inc. (AVBP) Latest News & Analysis
ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced its financial results for 2024 and shared updates on its progress as a clinical-stage biopharmaceutical company.
ArriVent's financial results and progress updates could signal growth or challenges ahead, impacting stock performance and investor sentiment in the biopharma sector.
ArriVent BioPharma has secured an exclusive license to develop and commercialize the antibody-drug conjugate MRG007 for GI cancers, outside Greater China, through a deal with Lepu Biopharma.
ArriVent BioPharma's exclusive license for MRG007 expands its product portfolio and market reach, potentially increasing future revenue and enhancing investor confidence in its growth prospects.
From 2001 to 2023, biotech and pharmaceutical companies accounted for about 24% of all initial public offerings (IPOs).
A significant portion of IPOs from biotech and pharmaceutical companies indicates strong investor interest and potential growth in these sectors, influencing market dynamics and investment strategies.
ArriVent BioPharma reported positive interim results for firmonertinib in NSCLC with 81.8% overall response rate. A webinar is scheduled for Sept. 9, 2024, to discuss these findings.
Strong clinical results for firmonertinib in treating NSCLC may boost ArriVent's stock value, indicating potential market success and increased investor confidence in the company's pipeline.
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet
8 months agoAnalysts' price targets for ArriVent BioPharma (AVBP) suggest a potential 27.3% upside, supported by consensus increases in earnings estimates.
Analysts' price targets suggest significant upside for ArriVent BioPharma, indicating potential growth. Increased earnings estimates further bolster positive sentiment around the stock.
Firmonertinib's clinical proof-of-concept data for treating EGFR PACC mutant NSCLC will be presented at the 2024 World Conference on Lung Cancer.
Positive data on firmonertinib for NSCLC could indicate a breakthrough treatment, potentially boosting the company's stock and attracting investment interest in biotech.
Frequently Asked Questions About AVBP Stock
What is Arrivent Biopharma Inc.'s (AVBP) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Arrivent Biopharma Inc. (AVBP) has a median price target of $39.00. The highest price target is $45.00 and the lowest is $36.00.
Is AVBP stock a good investment in 2025?
According to current analyst ratings, AVBP has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AVBP stock?
Wall Street analysts predict AVBP stock could reach $39.00 in the next 12 months. This represents a 115.0% increase from the current price of $18.14. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Arrivent Biopharma Inc.'s business model?
Arrivent Biopharma generates revenue through the discovery, development, and commercialization of therapeutic candidates in oncology. The company collaborates with research institutions and pharmaceutical partners to enhance the drug development process, focusing on addressing unmet medical needs in cancer treatment.
What is the highest forecasted price for AVBP Arrivent Biopharma Inc.?
The highest price target for AVBP is $45.00 from Michael Schmidt at Guggenheim, which represents a 148.1% increase from the current price of $18.14.
What is the lowest forecasted price for AVBP Arrivent Biopharma Inc.?
The lowest price target for AVBP is $36.00 from Robert Burns at HC Wainwright & Co., which represents a 98.5% increase from the current price of $18.14.
What is the overall AVBP consensus from analysts for Arrivent Biopharma Inc.?
The overall analyst consensus for AVBP is bullish. Out of 7 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $39.00.
How accurate are AVBP stock price projections?
Stock price projections, including those for Arrivent Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.